Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07547163

Patient Voice in the Treatment of Low-grade Gliomas: Use of Patient-reported Outcomes, Vorasidenib and Radiotherapy Compared

Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

View on ClinicalTrials.gov

Summary

The study aims to assess the direct patient-reported perception (PROs) of individuals affected by IDH-mutant, grade 2 gliomas undergoing radiotherapy or pharmacological treatment with vorasidenib. To evaluate quality of life, perception of treatment-related symptoms, and anxiety levels during therapy by comparing patients receiving radiotherapy with those receiving pharmacological treatment with vorasidenib. The control group will consist of patients with IDH-mutant, grade 2 gliomas who are under clinical and radiological follow-up only. To assess the feasibility of using PROMs in routine clinical practice. To analyze patient-reported critical issues in order to qualitatively improve care pathways.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

90

Start Date

2025-04-23

Completion Date

2027-10

Last Updated

2026-04-23

Healthy Volunteers

No

Interventions

DRUG

Vorasidenib

patients receiving pharmacological treatment with vorasidenib, isocitrate dehydrogenase (IDH) inhibitor;

PROCEDURE

Radiotherapy

Radiotherapy: patients treated with radiotherapy for residual disease or recurrence;

PROCEDURE

active surveillance

Follow-up: patients undergoing active surveillance with periodic follow-up including MRI and clinical evaluation.

Locations (1)

Fondazione IRCCS Istituto Neurologico Carlo Besta

Milan, Italy